ArticleFrontiers in pharmacology2022

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma.

Qian Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.